Shulin Yang

Shulin Yang

Auto-generated profile, based on publicly available information

Shulin Yang

Department of Reproductive Medicine and Genetics Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Transplantation Proceedings
Verified
Journal Article
Closed access
HJHae Woon Jung
Hae Woon Jung
HKHye Young Kim
Hye Young Kim
YLYoung-A Lee
Young-A Lee
HKHee Gyung Kang
Hee Gyung Kang
CSC.H. Shin
C.H. Shin
SYS.W. Yang
S.W. Yang

28 June 2024 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
BXBei Xu
Bei Xu
DGDirk Geerts
Dirk Geerts
JYJiaying Yuan
Jiaying Yuan
MWMengting Wang
Mengting Wang
ZLZhou Li
Zhou Li
LJLei JIN
Lei JIN
Can pregnancy outcomes following fresh elective single embryo transfer (eSET) in gonadotropin-releasing hormone (GnRH) antagonist protocols increase using a gonadotropin (Gn) step-down approach with cessation of GnRH antagonist on the day of hCG administration (hCG day) in patients with normal ovarian response? The modified GnRH antagonist protocol using the Gn step-down approach and cessation of GnRH antagonist on the hCG day is effective in improving live birth rates (LBRs) per fresh eSET cycle. Currently, there is no consensus on optimal GnRH antagonist regimens. Studies have shown that fresh GnRH antagonist cycles result in poorer pregnancy outcomes than the long GnRH agonist (GnRHa) protocol. Endometrial receptivity is a key factor that contributes to this phenomenon. An open label randomized controlled trial (RCT) was performed between November 2021 and August 2022. There were 546 patients allocated to either the modified GnRH antagonist or the conventional antagonist protocol at a 1:1 ratio. Both IVF and ICSI cycles were included, and the sperm samples used were either fresh or frozen from the partner, or from frozen donor ejaculates. The primary outcome was the LBRs per fresh SET cycle. Secondary outcomes included rates of implantation, clinical and ongoing pregnancy, miscarriage, and ovarian hyperstimulation syndrome (OHSS), as well as clinical outcomes of ovarian stimulation. Baseline demographic features were not significantly different between the two ovarian stimulation groups. However, in the intention-to-treat (ITT) population, the LBRs in the modified antagonist group were significantly higher than in the conventional group (38.1% [104/273] vs. 27.5% [75/273], relative risk 1.39 [95% CI, 1.09–1.77], P = 0.008). Using a per-protocol (PP) analysis which included all the patients who received an embryo transfer, the LBRs in the modified antagonist group were also significantly higher than in the conventional group (48.6% [103/212] vs. 36.8% [74/201], relative risk 1.32 [95% CI, 1.05–1.66], P = 0.016). The modified antagonist group achieved significantly higher implantation rates, and clinical and ongoing pregnancy rates than the conventional group in both the ITT and PP analyses (P < 0.05). The two groups did not show significant differences between the number of oocytes retrieved or mature oocytes, two-pronuclear zygote (2PN) rates, the number of embryos obtained, blastocyst progression and good-quality embryo rates, early miscarriage rates, or OHSS incidence rates (P > 0.05). A limitation of our study was that the subjects were not blinded to the treatment allocation in the RCT trial. Only women under 40 years of age who had a good prognosis were included in the analysis. Therefore, use of the modified antagonist protocol in older patients with a low ovarian reserve remains to be investigated. In addition, the sample size for Day 5 elective SET was small, so larger trials will be required to strengthen these findings. The modified GnRH antagonist protocol using the Gn step-down approach and cessation of GnRH antagonist on hCG day improved the LBRs per fresh eSET cycle in normal responders. This project was funded by grant 2022YFC2702503 from the National Key Research & Development Program of China and grant 2021140 from the Beijing Health Promotion Association. The authors declare no conflicts of interest. The RCT was registered in the Chinese Clinical Trial Registry; Study Number: ChiCTR2100053453. 21 November 2021. 23 November 2021

11 April 2024 in Connective Tissue Research
Verified
Journal Article
Closed access
SYShulin Yang
Shulin Yang
ZLZongzhe Li
Zongzhe Li
Purpose Congenital contractural arachnodactyly (CCA) is an extremely rare autosomal dominant connective tissue genetic disorder caused by pathogenic variants in FBN2. CCA is characterized by arachnodactyly, camptodactyly, contracture of major joints, scoliosis, pectus deformities, and crumpled ears, but rarely with lethal cardiovascular manifestations as in Marfan syndrome. It is imperative to conduct a comprehensive analysis and review of the pathogenesis of CCA resulting from pathogenic variants in FBN2 gene. Materials and Methods Using whole-exome sequencing and Sanger sequencing, we identified a novel pathogenic splice-altering variant (c.4472-3C>A) in intron 34 of FBN2 gene in a CCA pedigree. The transcriptional result of the splicing-altering variant was analyzed by RNA sequencing. We systematically analyzed the clinical manifestations of all reported cases of CCA caused by splicing-altering pathogenic variants and focused on all the pathogenic variants in FBN2 gene that are associated with severe cardiovascular manifestations. Results The splice-altering variant (c.4472-3C>A) in FBN2 was demonstrated to result in the exon 35 skipping and cause an in-frame deletion. Furthermore, we identified exons 31 to 35 may be a hotspot region in FBN2 gene associated with severe cardiovascular phenotype. Conclusions This study enriched the pathogenic spectrum of CCA and identified a hotspot region in FBN2 gene associated with severe cardiovascular manifestations. We recommend that patients carrying pathogenic variants in exons 31 to 35 of FBN2 pay more attention to cardiac evaluation.

29 September 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
MHM. Hu
M. Hu
SYS. Yang
S. Yang
YCY. Chen
Y. Chen
JKJung Hun Kang
Jung Hun Kang
YXY. Xu
Y. Xu

18 August 2026 in Archives of Medical Science
Verified
Journal Article
Closed access
PDF file
LWLuyao Wang
Luyao Wang
JCJiayun Chen
Jiayun Chen
Yifan ChuYifan Chu
Yifan Chu
YZYing Zhang
Ying Zhang
JYJing Yue
Jing Yue
SYShulin Yang
Shulin Yang
Introduction: We aimed to evaluate the clinical utility of autoimmune screening and the effectiveness of immunomodulatory treatment in preimplantation genetic testing (PGT) patients. Material and methods: In this retrospective cohort study, 151 PGT patients who experienced a failed first frozen embryo transfer (FET) were divided into two groups. Patients underwent immune marker screening before their second FET. Among them, 42 were classified into the immune-positive group and received targeted interventions, while 109 were categorized into the immune-negative group, which was further divided into an empirical medication subgroup (n = 43) and a no-intervention subgroup (n = 66). Baseline characteristics and pregnancy outcomes were analyzed using statistical methods, including univariate and multivariate logistic regression analyses. Results: We found that among PGT patients with first transfer failure, 28% (42/151) showed abnormal immune markers. Targeted therapy in immune-positive patients was associated with significantly improved clinical pregnancy rates compared to their first unscreened cycle (64.29% vs. 33.33%, p = 0.005), while reducing the miscarriage rate. In contrast, empirical immunomodulation in immune-negative patients did not provide any additional benefit in terms of live birth rate (39.53% vs. 43.94%, p = 0.649). Multivariate analysis confirmed that embryo quality was an independent positive predictor of both hCG positivity (p = 0.034) and clinical pregnancy (p = 0.022), whereas maternal age showed an inverse association with the likelihood of success (p < 0.05). Conclusions: Immune abnormalities are relatively prevalent in the PGT population. Targeted immunomodulatory interventions in immune-positive patients were associated with improved pregnancy outcomes. We recommend that these patients should undergo immune screening and targeted interventions before embryo transfer. However, empirical therapy in immune-negative individuals is unjustified.